Evidence map›Paper›PMID 31993101›Full record

ArticleInternational journal of physiology, pathophysiology and pharmacology2019

Serum levels of IL-6 and IL-17 in multiple sclerosis, neuromyelitis optica patients and healthy subjects.

Fereshte Ashtari, Reyhanehsadat Madanian, Vahid Shaygannejad, Sayyed Hamid Zarkesh, Keyvan Ghadimi

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of physiology, pathophysiology and pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Autoimmune Neuroinflammatory Diseases: Role of Interleukins.International journal of molecular sciences · 2023
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Evaluation of the serum level of osteoprotegerin and bone mineral density in postmenopausal women.International journal of physiology, pathophysiology and pharmacology · 2022
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Fereshte AshtariIsfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences Isfahan, Iran.
Reyhanehsadat MadanianIsfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences Isfahan, Iran.
Vahid ShaygannejadIsfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences Isfahan, Iran.
Sayyed Hamid ZarkeshDepartment of Immunology, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran.
Keyvan GhadimiSchool of Medicine, Isfahan University of Medical Sciences Isfahan, Iran.
Isfahan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStudies reported that evaluating the interleukin serum level of MS and NMO patients is helpful for differentiating these two diseases from each other. This study aimed to compare the level of IL-6 and IL-17 in MS and NMO patients and healthy subjects.

methodsThis study is a case control study that evaluated the serum level of IL-6 and IL-17 in MS and NMO patients in comparison to controls in patients who referred to Kashani hospital clinics. The level of serum IL-6 and IL-17 were measured by ELISA test in all patients. Participants were divided in to three groups include MS patients, NMO patients and controls and the level of IL-6 and IL-17 were compared in this three groups.

resultsMean of serum level of IL-6 in the NMO group was significantly lower than MS and healthy subject (P=0.02 for NMO and MS, P=0.001 for NMO and healthy subjects) but there was no significant difference between MS and healthy subjects (P=0.09). The mean of serum level of IL-17 in the MS and NMO were significantly higher than healthy subjects (P<0.001 for both). Also the mean of serum level of IL-17 in the MS was significantly higher than NMO (P=0.01). A positive significant correlation between age and serum level of IL-6 in all subjects (r=0.23, P=0.01). There was a positive significant correlation between age and serum level of IL-17 in MS and NMO patients (r=0.28, P=0.012).

conclusionUsing IL-17 and IL-6 were inflammatory markers to diagnosis of NMO, MS and healthy subjects.

Indexed as

interleukinMultiple sclerosisneuromyelitis optica (NMO)

Identifiers

PMID31993101
PMCPMC6971496
OpenAlexW3004195818

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.